Search

Your search keyword '"Merlijn van den Berg, J."' showing total 4 results
Start Over Author "Merlijn van den Berg, J."
4 results on '"Merlijn van den Berg, J."'

2. Marked variability in clinical presentation and outcome of patients with C1q immunodeficiency

Author

van Schaarenburg, Rosanne A., Schejbel, Lone, Truedsson, Lennart, Topaloglu, Rezan, Al-Mayouf, Sulaiman M., Riordan, Andrew, Simon, Anna, Kallel-Sellami, Maryam, Arkwright, Peter D., Åhlin, Anders, Hagelberg, Stefan, Nielsen, Susan, Shayesteh, Alexander, Morales, Adelaida, Tam, Schuman, Genel, Ferah, Berg, Stefan, Ketel, Arnoldus G., Merlijn van den Berg, J., Kuijpers, Taco W., Olsson, Richard F., Huizinga, Tom W.J., Lankester, Arjan C., and Trouw, Leendert A.

Published
2015
Full Text
View/download PDF

3. Two-year outcome of juvenile idiopathic arthritis in current daily practice: what can we tell our patients?

Author

Anink, Janneke, Dolman, Koert M., Merlijn van den Berg, J., van Veenendaal, Mira, Kuijpers, Taco W., van Rossum, Marion A. J., Other departments, Amsterdam institute for Infection and Immunity, and Paediatric Infectious Diseases / Rheumatology / Immunology

Abstract

Objectives This paper aims to evaluate disease course and outcome of patients in the first 2 years after diagnosis of juvenile idiopathic arthritis (JIA) when treated according to local standard of clinical care, focusing on achievement of inactive disease, functional ability and radiological joint damage. Methods A retrospective inception cohort study of children with JIA, diagnosed between January 2003 and June 2007 and treated in referral centres in Amsterdam, was carried out. Disease status was determined for every outpatient-clinic visit. Data regarding medication, functional outcome and radiography were recorded. Results One hundred and forty-nine consecutive newly diagnosed JIA patients were included. Median age at diagnosis was 11.8 years; median follow-up was 33 months. Synthetic DMARDs (sDMARDs) were used by 95% of patients, including methotrexate in 85%, sulfasalazine in 41% and biologics in 20%. sDMARDs were started within median 1 month after diagnosis. During follow-up, 77% of patients achieved a total of 244 episodes of inactive disease (ID). ID was reached after median 10 months. No baseline predictive factors for achievement of ID could be identified. After 2 years a median CHAQ score of 0.6 was reported. Radiological joint damage occurred at some point in 18 patients (12%); 10 of these patients developed erosions within median 20 months after their first clinic visit. Conclusion With current management strategies in daily clinical practice, 77% of newly diagnosed JIA patients achieved a first episode of inactive disease within a median of 10 months. After 2 years, patients reported moderate functional disability and more than 10% showed radiological evidence of joint damage

Published
2012

4. Two-year outcome of juvenile idiopathic arthritis in current daily practice: what can we tell our patients?

Author

Anink J, Dolman KM, Merlijn van den Berg J, van Veenendaal M, Kuijpers TW, and van Rossum MA

Subjects
Adolescent, Antirheumatic Agents adverse effects, Arthritis, Juvenile diagnostic imaging, Arthritis, Juvenile physiopathology, Arthrography, Chi-Square Distribution, Child, Disability Evaluation, Female, Humans, Joints pathology, Logistic Models, Male, Netherlands, Predictive Value of Tests, Recovery of Function, Remission Induction, Retrospective Studies, Severity of Illness Index, Standard of Care, Time Factors, Treatment Outcome, Antirheumatic Agents therapeutic use, Arthritis, Juvenile drug therapy, Joints drug effects
Abstract

Objectives: This paper aims to evaluate disease course and outcome of patients in the first 2 years after diagnosis of juvenile idiopathic arthritis (JIA) when treated according to local standard of clinical care, focusing on achievement of inactive disease, functional ability and radiological joint damage., Methods: A retrospective inception cohort study of children with JIA, diagnosed between January 2003 and June 2007 and treated in referral centres in Amsterdam, was carried out. Disease status was determined for every outpatient-clinic visit. Data regarding medication, functional outcome and radiography were recorded., Results: One hundred and forty-nine consecutive newly diagnosed JIA patients were included. Median age at diagnosis was 11.8 years; median follow-up was 33 months. Synthetic DMARDs (sDMARDs) were used by 95% of patients, including methotrexate in 85%, sulfasalazine in 41% and biologics in 20%. sDMARDs were started within median 1 month after diagnosis. During follow-up, 77% of patients achieved a total of 244 episodes of inactive disease (ID). ID was reached after median 10 months. No baseline predictive factors for achievement of ID could be identified. After 2 years a median CHAQ score of 0.6 was reported. Radiological joint damage occurred at some point in 18 patients (12%); 10 of these patients developed erosions within median 20 months after their first clinic visit., Conclusions: With current management strategies in daily clinical practice, 77% of newly diagnosed JIA patients achieved a first episode of inactive disease within a median of 10 months. After 2 years, patients reported moderate functional disability and more than 10% showed radiological evidence of joint damage.

Published
2012

Catalog

Books, media, physical & digital resources
See catalog results